Johnathan W Kirkwood, B.Sc. – Regular Affair & Quality
Mr. Kirkwood, has over 20 years experience serving the healthcare industry in the areas of Regulatory Affairs. He has held senior management positions in Regulatory Affairs, including Cangene Corporation (2004-2009); Eli Lilly Canada Inc. (2002-2004); Boehringer Ingelheim (Canada) Ltd. (1999- 2002); Pharmacia & Upjohn Inc. (1996 –1999). Mr Kirkwood was responsible for regulatory submissions in Canada , Europe , US, and other countries for many recombinant protein products (rhGH, rhGM-CSF), plasma-derived immunoglobulin (hyperimmune) products, Xigris (activated Protein C), Forteo (teriparatide), and the global regulatory approval of Strattera (atomoxetine) and Cialis (tadalafil).
His current and past clients include academic institutions with gene or cell therapy projects entering clinical trials, small biotech companies with multiple early-phase candidate products, established pharmaceutical manufacturing firms developing new dosage forms for existing marketed products, and foreign pharmaceutical companies seeking to enter the North American market.